- Quarter highlighted by progress with vilobelimab in several indications:
- Encouraging Phase III topline results reported in patients with severe COVID-19; discussions with regulatory authorities already underway
- Final data from Phase IIa open-label study in patients with pyoderma gangrenosum presented at 2022 AAD Annual Meeting; end-of-Phase II meeting with FDA scheduled for mid-2022
- In Phase II trial in cutaneous squamous cell carcinoma, second dosing cohort of combination arm started; enrollment in monotherapy arm continuing with 8 patients enrolled with data expected in Q3 2022
- Clinical development in hidradenitis suppurativa and ANCA-associated vasculitis halted for the time being
- Introduced new pipeline program, INF904, an oral small molecule inhibitor of C5aR; planned to enter the clinic later this year
- Cash, cash equivalents and financial assets of approximately €99.3 million as of March 31, 2022, expected to fund operations well into H2 2024
JENA, Germany, May 12, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today financial and operating results for the three months ended March 31, 2022 and provided a business update.
Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, commented: “Following a recent internal strategic review, we are announcing the Company’s updated key priorities and strategy. With final data now available from our Phase IIa study, we intend to move vilobelimab into a pivotal program in pyoderma gangrenosum and advance INF-904, our small molecule C5aR inhibitor, into first-in-human testing this year. Additionally, with the encouraging topline Phase III results we saw with vilobelimab in treating severe COVID-19 patients, we are now discussing our data with regulatory authorities to assess a potential path towards approval. With all of these important activities, we decided to halt the Phase III program in hidradenitis suppurativa and not to advance vilobelimab in AAV for the time being to prioritize the best use of our resources. We are excited about InflaRx’s potential to develop effective new treatments to improve the lives of patients suffering from neutrophil-driven inflammatory diseases.”
Recent Highlights – Progress with Vilobelimab in Several Indications
Severe COVID-19: On March 31, 2022, InflaRx announced topline results from the Phase III part of the global Phase II/III PANAMO trial evaluating vilobelimab in mechanically ventilated patients with COVID-19. A total of 369 patients were enrolled. Vilobelimab treatment resulted in a relative reduction in 28-day all-cause mortality of 23.9% compared to placebo (vilobelimab 31.7% versus placebo 41.6%, p=0.094), which was not statistically significant using site-stratified Cox regression analysis as pre-specified in the final statistical analysis plan. At the recommendation of regulatory authorities, during the course of the trial, the Company changed the statistical analysis method for the primary endpoint. The original protocol-specified analysis would have resulted in a statistically significant p-value of 0.027. Additionally, logistic regression analyses of 28-day all-cause mortality resulted in p-values of <0.05 for 3 out of the 4 pre-specified analyses.
A pre-specified analysis of patients from Western European countries showed a relative reduction in 28-day all-cause mortality of 43% (p=0.014), suggesting an improvement in mortality in line with the reported Phase II data from the PANAMO trial.
Importantly, 60-day all-cause mortality, a key secondary endpoint, showed a continued reduction of mortality in the vilobelimab arm.
The Company is engaged in ongoing discussions with regulatory authorities to determine next steps towards a potential approval in this indication.
Pyoderma Gangrenosum (PG): InflaRx presented final data from an open-label, multi-center Phase IIa exploratory study evaluating the safety and efficacy of vilobelimab in patients with moderate to severe PG at the American Academy of Dermatology Association (AAD) Annual Meeting on March 26, 2022 in an oral late-breaker session by Afsaneh Alavi, MD, Associate Professor of Dermatology, Mayo Clinic. The final results showed a strong dose-dependent effect in the highest dose cohort of 2400 mg, with 6 out of 7 patients showing a clinical remission (Physician Global Assessment (PGA) score ≤ 1) and closure of the target ulcer. The seventh patient showed a slight improvement (PGA score 4) with a decrease of the target ulcer area of over 50%. During the follow-up period, ulcers remained closed two months after treatment completion in all but one patient, and a sustained suppression of C5a was observed for up to 20 days after the last dosing. With these compelling results, an end-of-Phase II meeting has been scheduled with the FDA for mid-2022 to discuss the pivotal program in this indication.
Cutaneous Squamous Cell Carcinoma (cSCC): InflaRx is developing vilobelimab for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cSCC. An open-label, non-comparative, two-stage, Phase II trial in cSCC is ongoing and has two independent arms: vilobelimab alone (Arm A) and vilobelimab in combination with pembrolizumab (Arm B).
Enrollment continues in the monotherapy Arm A. Eight patients are now enrolled in this arm. Data are expected to be available in the third quarter of 2022.
In February 2022, the Company announced the start of the second dosing cohort of Arm B. The interim analysis in this arm is expected after ten patients have been treated and are evaluable for response assessment at the recommended Phase II dose level, which will be selected based on data from the safety run-in phase of the study. These Arm B interim data, which are a prerequisite to move to the second stage of the trial, are expected to be available in the second half of 2023.
Hidradenitis Suppurativa (HS) and ANCA-Associated Vasculitis (AAV): In response to its recent strategic pipeline review, the Company has decided to move vilobelimab into pivotal testing in pyoderma gangrenosum and to halt the development of vilobelimab in HS and not to advance vilobelimab in AAV for the time being.
New Development Program Introduced
InflaRx announced in January 2022 a new pipeline program, INF904, an oral small molecule inhibitor of C5aR. InflaRx has been granted a composition of matter patent for INF904 and associated compounds by the U.S. Patent and Trademark Office and has completed investigational new drug (IND)-enabling (preclinical) studies that demonstrated no obvious toxicological findings even in the highest dose groups in required GLP toxicity analyses.
The Company expects to initiate a Phase I program in the second half of 2022 and plans to study INF904 in complement-mediated, chronic autoimmune and inflammatory diseases where oral administration is the preferred choice for patients.
Financial Highlights – Q1 2022
Research and Development Expenses
Research and development expenses for the three months ended March 31, 2022 increased by €5.6 million to €10.5 million compared to the three months ended March 31, 2021. This increase was primarily due to the completion of Phase III clinical development of vilobelimab for the treatment of COVID-19. This led to an increase of €3.1 million in manufacturing costs, which significantly contributed to an overall increase of €5.1 million in third-party expenses. The €0.5 million increase in personnel expenses was mainly related to equity-settled share-based compensation.
General and Administrative Expenses
General and administrative expenses increased by €1.4 million to €4.4 million for the three months ended March 31, 2022, from €3.0 million for the three months ended March 31, 2021. This increase is attributable to higher personnel expenses from equity-settled share-based compensation recognized in personnel expenses of €0.4 million. Additionally, legal, consulting and other expenses increased to €1.9 million for the three months ended March 31, 2022, from €1.0 million for the three months ended March 31, 2021.
Net Financial Result
Net financial result decreased by €0.9 million to €0.9 million for the three months ended March 31, 2022, from €1.8 million for the three months ended March 31, 2021. This decrease is mainly attributable to lower foreign exchange gains, which decreased by €1.3 million, and higher foreign exchange losses of €0.3 million. Other finance expenses for the three months ended March 31, 2022 included a €48 thousand gain from a reduction in the allowance for expected credit loss on marketable securities.
Net Loss
Net loss for the three months ended March 31, 2022 was €14.0 million, compared to €6.1 million for the three months ended March 31, 2021.
On March 31, 2022, the Company’s total funds available were approximately €99.3 million, composed of cash and cash equivalents of €40.1 million and financial assets of €59.2 million. With the Company’s adjusted strategy, these funds are expected to finance operations well into the second half of 2024.
Net Cash Used in Operating Activities
Net cash used in operating activities increased to €12.9 million in the three months ended March 31, 2022, from €10.4 million in the three months ended March 31, 2021.
Additional information regarding these results and other relevant information is included in the notes to the unaudited interim condensed consolidated financial statements as of March 31, 2022 and the three months ended March 31, 2022 and 2021, as well as the consolidated financial statements as of and for the year ended December 31, 2021 in “ITEM 18. Financial Statements,” in InflaRx’s Annual Report on Form 20-F for the year ended December 31, 2021 as filed with the U.S. Securities and Exchange Commission.
InflaRx N.V. and subsidiaries
Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three months ended March 31, 2022 and 2021
| For the three months ended March 31, | |||||
| (in €, except for share data) | 2022 (unaudited) | 2021 (unaudited) | |||
| Operating Expenses | |||||
| Research and development expenses | (10,471,923 | ) | (4,906,885 | ) | |
| General and administrative expenses | (4,387,443 | ) | (3,022,338 | ) | |
| Total Operating Expenses | (14,859,366 | ) | (7,929,224 | ) | |
| Other income | 1,593 | 5,462 | |||
| Other expenses | (565 | ) | (565 | ) | |
| Operating Result | (14,858,338 | ) | (7,924,327 | ) | |
| Finance income | 27,962 | 22,962 | |||
| Finance expenses | (24,586 | ) | (3,684 | ) | |
| Foreign exchange result | 727,933 | 1,731,671 | |||
| Other financial result | 125,000 | 48,000 | |||
| Income Taxes | — | — | |||
| Loss for the Period | (14,002,030 | ) | (6,125,378 | ) | |
| Share Information | |||||
| Weighted average number of shares outstanding | 44,203,763 | 33,807,774 | |||
| Loss per share (basic/diluted) | (0.32 | ) | (0.18 | ) | |
| Loss for the Period | (14,002,030 | ) | (6,125,378 | ) | |
| Other comprehensive income (loss) that may be reclassified to profit or loss in subsequent periods: | |||||
| Exchange differences on translation of foreign currency | 1,309,875 | 3,504,699 | |||
| Total Comprehensive Loss | (12,692,154 | ) | (2,620,679 | ) | |
InflaRx N.V. and subsidiaries
Unaudited Condensed Consolidated Statements of Financial Position
as of March 31, 2022 and December 31, 2021
in € | March31, 2022 (unaudited) | December31, 2021 | |||
| ASSETS | |||||
| Non-current assets | |||||
| Property and equipment | 251,713 | 274,373 | |||
| Right-of-use assets | 1,314,691 | 1,408,078 | |||
| Intangible assets | 209,818 | 235,216 | |||
| Other assets | 331,539 | 336,566 | |||
| Financial assets | 9,272,352 | 27,206,990 | |||
| Total non-current assets | 11,380,114 | 29,461,224 | |||
| Current assets | |||||
| Current other assets | 12,521,363 | 10,983,458 | |||
| Current tax assets | 1,154,604 | 1,282,177 | |||
| Financial assets | 49,925,236 | 57,162,266 | |||
| Cash and cash equivalents | 40,096,286 | 26,249,995 | |||
| Total current assets | 103,697,489 | 95,677,896 | |||
| TOTAL ASSETS | 115,077,603 | 125,139,120 | |||
| EQUITY AND LIABILITIES | |||||
| Equity | |||||
| Issued capital | 5,304,452 | 5,304,452 | |||
| Share premium | 280,310,744 | 280,310,744 | |||
| Other capital reserves | 33,121,984 | 30,591,209 | |||
| Accumulated deficit | (227,977,709 | ) | (213,975,679 | ) | |
| Other components of equity | 4,360,146 | 3,050,270 | |||
| Total equity | 95,119,617 | 105,280,996 | |||
| Non-current liabilities | |||||
| Lease liabilities | 973,905 | 1,066,354 | |||
| Other liabilities | 35,628 | 35,019 | |||
| Total non-current liabilities | 1,009,533 | 1,101,373 | |||
| Current liabilities | |||||
| Trade and other payables | 9,502,770 | 8,574,244 | |||
| Liabilities from government grants received | 8,300,000 | 8,300,000 | |||
| Lease liabilities | 369,676 | 366,171 | |||
| Employee benefits | 644,646 | 1,378,130 | |||
| Other financial liabilities | 131,362 | 138,206 | |||
| Total current liabilities | 18,948,452 | 18,756,751 | |||
| Total Liabilities | 19,957,985 | 19,858,124 | |||
| TOTAL EQUITY AND LIABILITIES | 115,077,603 | 125,139,120 | |||
InflaRx N.V. and subsidiaries
Unaudited Condensed Consolidated Statements of Changes in Shareholders’ Equity for the three months ended March 31, 2022 and 2021
| (in €, except for share data) | Issued capital | Share premium | Other capital reserves | Accumulated deficit | Other components of equity | Total equity | |||||||||
| Balanceas ofJanuary 1, 2022 | 5,304,452 | 280,310,744 | 30,591,209 | (213,975,679 | ) | 3,050,271 | 105,280,996 | ||||||||
| Loss for the period | — | — | — | (14,002,030 | ) | — | (14,002,030 | ) | |||||||
| Exchange differences on translation of foreign currency | — | — | — | — | 1,309,875 | 1,309,875 | |||||||||
| Total comprehensive loss | — | — | — | (14,002,030 | ) | 1,309,875 | (12,692,155 | ) | |||||||
| Equity-settled share-based payments | — | — | 2,530,775 | — | — | 2,530,775 | |||||||||
| Balanceas ofMarch 31, 2022 | 5,304,452 | 280,310,744 | 33,121,984 | (227,977,709 | ) | 4,360,146 | 95,119,617 | ||||||||
| Balance as of January 1, 2021 | 3,387,410 | 220,289,876 | 26,259,004 | (168,345,620 | ) | (3,726,790 | ) | 77,863,880 | |||||||
| Loss for the period | — | — | — | (6,125,378 | ) | — | (6,125,378 | ) | |||||||
| Exchange differences on translation of foreign currency | — | — | — | — | 3,504,699 | 3,504,699 | |||||||||
| Total comprehensive loss | — | — | — | (6,125,378 | ) | 3,504,699 | (2,620,679 | ) | |||||||
| Issuance of common shares and warrants | 1,873,203 | 63,269,346 | — | — | — | 65,142,549 | |||||||||
| Transaction costs | — | (4,219,222 | ) | — | — | — | (4,219,222 | ) | |||||||
| Equity-settled share-based payments | — | — | 1,721,270 | — | — | 1,721,270 | |||||||||
| Share options exercised | 41,741 | 921,994 | — | — | — | 963,735 | |||||||||
| Balance as of March 31, 2021 | 5,302,354 | 280,261,994 | 27,980,274 | (174,470,998 | ) | (222,091 | ) | 138,851,532 | |||||||
InflaRx N.V. and subsidiaries
Unaudited Condensed Consolidated Statements of Cash Flows for the three months ended March 31, 2022 and 2021
in € | For the three months ended March 31, 2022 (unaudited) | For the three months ended March31, 2021 (unaudited) | |||
| Operating activities | |||||
| Loss for the period | (14,002,030 | ) | (6,125,378 | ) | |
| Adjustments for: | |||||
| Depreciation & amortization of property and equipment, right-of-use assets and intangible assets | 153,321 | 168,343 | |||
| Net finance income | (856,308 | ) | (1,798,949 | ) | |
| Share-based payment expense | 2,530,775 | 1,721,270 | |||
| Net foreign exchange differences | 135,826 | 193,847 | |||
| Changes in: | |||||
| Other assets | (1,405,328 | ) | (2,739,152 | ) | |
| Employee benefits | (732,876 | ) | (952,820 | ) | |
| Other liabilities | (6,844 | ) | 240,229 | ||
| Trade and other payables | 928,526 | (1,150,252 | ) | ||
| Interest received | 420,916 | 33,189 | |||
| Interest paid | (24,641 | ) | (3,780 | ) | |
| Net cash used in operating activities | (12,858,662 | ) | (10,413,453 | ) | |
| Investing activities | |||||
| Purchase of intangible assets, property and equipment | (7,828 | ) | (17,062 | ) | |
| Purchase of current financial assets | — | (14,985,026 | ) | ||
| Proceeds from the maturity of financial assets | 26,488,950 | 13,952,522 | |||
| Net cash from/ (used in)investing activities | 26,481,122 | (1,049,566 | ) | ||
| Financing activities | |||||
| Proceeds from issuance of common shares | — | 65,142,549 | |||
| Transaction costs from issuance of common shares | — | (4,219,222 | ) | ||
| Proceeds from exercise of share options | — | 963,735 | |||
| Repayment of lease liabilities | (90,806 | ) | (90,716 | ) | |
| Net cash from/ (used in) financing activities | (90,806 | ) | 61,796,346 | ||
| Net increase/(decrease) in cash and cash equivalents | 13,531,653 | 50,333,328 | |||
| Effect of exchange rate changes on cash and cash equivalents | 314,639 | 2,432,654 | |||
| Cash and cash equivalents at beginning of period | 26,249,995 | 25,968,681 | |||
| Cash and cash equivalents at end of period | 40,096,286 | 78,734,662 | |||
About InflaRx N.V.:
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary technology to discover and develop first-in-class or best-in-class, potent and specific inhibitors of C5a and C5aR. Complement C5a and its receptor C5aR are powerful inflammatory mediators involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com.
The COVID-19 related work described herein is partly funded by the German Federal Government through grant number 16LW0113 (Vilo-Covid). All responsibility for the content of this work lies with InflaRx.
Contacts:
InflaRx N.V.
Jordan Zwick – Chief Strategy Officer
Email: IR@inflarx.de
Tel: +1 917-338-6523
MC Services AG
Katja Arnold, Laurie Doyle, Andreas Jungfer
Email: inflarx@mc-services.eu
Europe: +49 89-210 2280
US: +1-339-832-0752
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential” or “continue” and similar expressions. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, development of vilobelimab for mechanically ventilated COVID-19 patients; future analysis of our Phase II/III PANAMO trial and interactions with regulators regarding the results of the trial and potential regulatory approval pathways; the impact of the COVID-19 pandemic on us; the timing and our ability to commence and conduct clinical trials; potential results from current or potential future collaborations; our ability to make regulatory filings, obtain positive guidance from regulators, and obtain and maintain regulatory approvals for our product candidates; our intellectual property position; our ability to develop commercial functions; expectations regarding clinical trial data; decisions regarding the strategic direction of our company; our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies; the industry in which we operate; the trends that may affect the industry or us; our status as an emerging growth company and/or foreign private issuer; and the risks, uncertainties and other factors described under the heading “Risk Factors” in InflaRx’s periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
